Search

Your search keyword '"OVERALL survival"' showing total 7 results
7 results on '"OVERALL survival"'

1. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.

Author

Cookson, Michael S.

Subjects
*NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

Published
2024

2. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.

Author

Joszt, Laura

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *LUNG cancer, *DISEASE progression, *EVALUATION of human services programs, *COMBINATION drug therapy, *EPIDERMAL growth factor receptors, *LUNG tumors, *CHEMORADIOTHERAPY, *MEDICAL care research, *TUMOR classification, *TREATMENT effectiveness, *CANCER patients, *ANAPLASTIC lymphoma kinase, *SURVIVAL analysis (Biometry), *QUALITY of life, *PROGRESSION-free survival, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival, *CHEMICAL inhibitors
Abstract

The article reports on the results of the 3 EMPOWER-Lung 3 study that were presented at the 2023 European Society for Medical Oncology Congress, showing that cemiplimab plus chemotherapy showed better favorable survival benefits and patient-reported outcomes (PRO) in patients with advanced non-small cell lung cancer (NSCLC). Also cited are the median overall survival (OS), objective response rate (ORR), and progression-free survival (PFS) study results.

Published
2023

3. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.

Author

SAYLOR, BENJAMIN P.

Subjects
*THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *ANTIANDROGENS, *CASTRATION-resistant prostate cancer, *PLACEBOS, *PROSTATE tumors, *TREATMENT effectiveness, *METASTASIS, *DISEASE progression, *OVERALL survival
Abstract

The article focuses on the results of the phase three ARASENS trial on the effectiveness of darolutamide as a treatment in patients with metastatic hormone-sensitive prostate cancer, which were presented at the 2024 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois. Topics discussed include the improvementin the overall survival and delay time to progression to metastatic castration-resistant disease, and the definition of postprogression survival.

Published
2024

4. Prostate cancer treatment deintensification: When less is more.

Author

COOKSON, MICHAEL S.

Subjects
*PROSTATE tumors treatment, *DISEASE progression, *ANTIANDROGENS, *INDIVIDUALIZED medicine, *TREATMENT effectiveness, *RISK assessment, *ADVERSE health care events, *DISEASE management, *PROSTATE tumors, *OVERALL survival
Abstract

In the article, the author discusses updates in the treatment of patients with advanced and metastatic prostate cancer, particularly the clinical trials showing the efficacy of treatment deintensification in the proper clinical context. Other topics include the potential benefits of deintensification like reduction of treatment-related adverse events (TRAE) and the various deintensification methods like radiation therapy with omission of androgen deprivation therapy (ADT).

Published
2023

5. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG efficacy, *PATIENT aftercare, *COMBINATION drug therapy, *COLLEGE teacher attitudes, *TREATMENT effectiveness, *BENZAMIDE, *PROGRESSION-free survival, *OVERALL survival, *THERAPEUTICS
Abstract

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.

Published
2023

6. Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.

Author

McNulty, Rose

Subjects
*MULTIPLE myeloma treatment, *DISEASE progression, *BONE marrow transplantation, *TREATMENT effectiveness, *PROGRESSION-free survival, *OVERALL survival
Abstract

The article discusses research that shows allogeneic stem cell transplant (allo-SCT) may not significantly benefit most patients with multiple myeloma. It considers the overall survival and progression-free survival after allo-SCT. The feasibility of alternatives such as CAR T-cell or bispecific T-cell engager therapies is suggested. The findings were presented at the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana.

Published
2023

7. Hypertension predicts worse outcomes for patients undergoing nephroureterectomy for UTUC.

Author

SAYLOR, BENJAMIN P.

Subjects
*URINARY organ surgery, *ONCOLOGIC surgery, *HYPERTENSION, *CAUSES of death, *NEPHRECTOMY, *URETHRA surgery, *SURGERY, *PATIENTS, *CANCER relapse, *TREATMENT effectiveness, *OVERALL survival, *DISEASE complications, MORTALITY risk factors
Abstract

The article provides information on data presented at the American Urological Association 2023 Annual Meeting in Chicago, Illinois which reported that hypertension is an independent predictor of worsened oncologic and survival outcomes in patients undergoing radical nephroureterectomy for the treatment of upper tract urothelial cancer (UTUC). Topics include rate of high tumor grade observed in patients with hypertension and overall survival of patients with hypertension.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results